JP Morgan cuts Xylem price target to $118, keeps Neutral rating

scanx
Reviewed by
Suketu GScanX News Team
Key Highlights
  • JP Morgan lowers Xylem price target from $137 to $118
  • Analyst Mark Strouse maintains Neutral rating on the stock
  • Price target reduction amounts to $19 per share
powered bylight_fuzz_icon
53989080

*this image is generated using AI for illustrative purposes only.

JP Morgan analyst Mark Strouse has lowered the price target for Xylem Inc from $137 to $118 while maintaining a Neutral rating on the stock.

The revision reduces the implied upside potential for investors by $19 per share compared to the previous target. The firm continues to hold a Neutral stance, indicating no immediate recommendation to buy or sell the shares at current levels.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

What specific macroeconomic or operational factors drove the $19 reduction in Xylem's price target?

How are other major financial institutions adjusting their price targets for Xylem in response to this revision?

Will the lowered target influence institutional investor sentiment and trading volume for Xylem shares in the near term?

Mizuho lowers Xylem price target to $110, maintains Neutral rating

scanx
Reviewed by
Anirudha BScanX News Team
Key Highlights
  • Mizuho lowered Xylem Inc's price target from $130 to $110
  • The firm maintained a Neutral rating on the stock
  • Analyst Brett Linzey is responsible for the coverage
powered bylight_fuzz_icon
53631889

*this image is generated using AI for illustrative purposes only.

Xylem Inc saw its price target reduced by Mizuho, with analyst Brett Linzey lowering the figure from $130 to $110. Despite the reduction in valuation, the firm maintained its Neutral rating on the stock.

Analyst Action Details

The adjustment reflects Mizuho's updated outlook on the company. The key changes from the latest research note are outlined below:

Metric Previous Value New Value
Price Target $130 $110
Rating Neutral Neutral

No further details regarding the rationale for the price target reduction were provided in the source material.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

What specific macroeconomic headwinds or sector-specific challenges are driving Mizuho's revised outlook for Xylem?

How are other major financial institutions adjusting their price targets for Xylem in response to recent industry trends?

Will Xylem's upcoming earnings report provide sufficient guidance to stabilize investor sentiment following this valuation cut?

More News on Xylem